当前位置: X-MOL 学术Vet. Microbiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Construction and evaluation of recombinant Lactobacillus plantarum NC8 delivering one single or two copies of G protein fused with a DC-targeting peptide (DCpep) as novel oral rabies vaccine
Veterinary Microbiology ( IF 3.3 ) Pub Date : 2020-10-24 , DOI: 10.1016/j.vetmic.2020.108906
Jianzhong Wang 1 , Haoyan Jiang 1 , Rui Yang 1 , Shubo Zhang 1 , Weijing Zhao 1 , Jingtao Hu 1 , Yanlong Jiang 1 , Wentao Yang 1 , Haibin Huang 1 , Chunwei Shi 1 , Guilian Yang 1 , Hualei Wang 2 , Chunfeng Wang 1 , Na Feng 3
Affiliation  

Rabies remains an important public health threat in most developing countries. To develop a more effective and safe oral vaccine against rabies, we constructed recombinant Lactobacillus plantarum NC8 carrying one or two copies of the G gene with a dendritic cell-targeting peptide (DCpep) fused at the C-terminal designated NC8-pSIP409-sRVG or NC8-pSIP409-dRVG, respectively. The immunogenicity and protective efficacy of these recombinant Lactobacillus plantarum against RABV were evaluated by oral administration in a mouse model. The results showed that recombinant NC8-pSIP409-dRVG possessed more G protein, resulting in more functional maturation of DCs. After three cycle of oral immunization, NC8-pSIP409-dRVG induced significantly higher levels of specific IgG antibody and mixed Th1/Th2 with a strong Th1-biasd immune response in mice. Most importantly, although the titers of RABV neutralizing antibody (VNA) were below the threshold of 0.5 IU/mL, the NC8-pSIP409-dRVG could protect 60 % of inoculated mice against lethal RABV challenge. These data reveal that recombinant NC8-pSIP409-dRVG may be a novel and promising oral vaccine candidate to prevent and control of animal rabies.

更新日期:2020-11-05
down
wechat
bug